Something quietly significant happened this autumn. The U.S. Food and Drug Administration opened a public docket on psychedelics — the kind of regulatory housekeeping that usually puts people to sleep — and roughly 600 submissions poured in. Clinicians, researchers, patient advocates, veterans, trade groups, religious practitioners, and a surprising number of ordinary citizens who’ve had their lives rearranged by a mushroom journey all wrote in. The comment window closed on October 5th, and the full set is now public.

If you’re weighing whether to attend a psychedelic retreat, or you’re watching the slow march of psychedelic-assisted therapy toward mainstream medicine, these comments matter. They’re a snapshot of where the field agrees, where it’s fighting itself, and what the regulators are being asked to protect. I spent a long weekend reading through the submissions. Here’s what stood out — and what it means for anyone considering plant medicine or psychedelics as a path toward addiction recovery, trauma work, or healing stuck patterns.

What the Docket Actually Is (and Why You Should Care)

Back in July, the FDA held a Part 15 public hearing — basically an open-mic session for stakeholders to speak directly to the agency about how it should think about psychedelics. The hearing itself was notable for what wasn’t there: no sharp questions from the panel, no cross-examination, just presentations into the void. The real substance was always going to come later, in writing, through the companion docket.

And come it did. Just under 500 of the 610 submissions are genuinely distinct — the rest are form letters from coordinated campaigns, plus a handful of duplicates and some truly odd entries (one anonymous submitter wrote only “Nice” and attached a PDF about buying anti-nausea medication online; another argued, apropos of nothing, for better food traceability rules). Welcome to open government.

The reason this matters to retreat-seekers and the broader psychedelic healing community is simple: whatever framework the FDA eventually builds will shape which substances get approved, who’s allowed to administer them, how much therapy must be bundled with the drug, and how the whole thing gets paid for. That has knock-on effects on the underground, on ceremonial traditions, and on the retreat industry that currently exists in the grey zones outside U.S. jurisdiction.

Who Showed Up — and What They Wanted

The crowd was wide. You had major industry players — the companies developing MDMA, psilocybin, and ibogaine therapies — alongside academic researchers, physician groups, veterans’ organizations, patient advocacy nonprofits, religious use practitioners, harm reduction groups, and a healthy chunk of individuals writing from personal experience.

Overall sentiment skewed supportive. Most submitters want the FDA to approve psychedelic medicines and want it to happen without unnecessary delay. But “supportive” hides a lot of nuance. The real story is in how the pro-psychedelic camp disagrees with itself about how approval should happen, what rules should ride alongside it, and what role traditional psychotherapy should play.

Here are the broad groupings I saw:

• Drug developers and biotech: wanting a clear, predictable path, often with lighter psychotherapy requirements that would make their business models workable.
• Clinicians and therapists: largely insisting that psychological support is not optional window dressing but the active mechanism of change.
• Veterans and patient groups: urging speed, citing the suicide and overdose numbers, pointing to the growing evidence base for addiction recovery and PTSD.
• Religious and ceremonial-use practitioners: asking the FDA not to accidentally criminalize or over-medicalize traditions that have operated for generations.
• Harm reduction and policy groups: focused on access, equity, and keeping decriminalization efforts intact alongside medicalization.

The Fault Lines: Where Stakeholders Actually Disagree

If you only read the headlines, you’d think the psychedelic field speaks with one voice. It doesn’t. The docket exposes several genuine disagreements that will shape the next decade.

The Psychotherapy Question

This is the big one. Should an approved psychedelic drug come packaged with mandatory therapy sessions — a specific number of hours, with trained providers, before and after dosing? Or should the drug be approved as a drug, with therapy being a clinical judgment call like it is with antidepressants?

Developers tend to want flexibility here, partly because mandated therapy is expensive to deliver and hard to standardize across insurance systems. Therapists and many researchers push back hard: the whole point of ayahuasca, psilocybin, or MDMA work, they argue, is that the substance opens a window and the therapeutic container determines what happens inside it. Strip out the preparation and integration and you don’t have medicine — you just have a chemical experience.

Anyone who has sat in ayahuasca ceremony will recognise this debate. The brew doesn’t heal you. The ceremony, the facilitator, the dieta beforehand, the integration afterwards — those are what turn a difficult night into actual change. Translating that wisdom into FDA language is proving tricky.

Product-Specific Rules and Trial Safeguards

A second fault line runs through how prescriptive the FDA should be about trial design and post-approval monitoring. Should every psychedelic drug come with a Risk Evaluation and Mitigation Strategy (REMS) — the special program used for medicines with serious safety concerns? Many commenters say yes, especially given the vulnerability of patients during dosing and the small but real risk of adverse psychological events.

Others worry that heavy REMS requirements will push psychedelic therapy out of reach for anyone who isn’t wealthy and well-insured, recreating the two-tier access problem that already plagues ketamine clinics. The equity argument is loud in the docket, and rightly so.

Who Gets to Be in the Room

Related, but distinct: who’s qualified to administer psychedelic therapy? Must facilitators be licensed psychologists or psychiatrists? Can social workers, licensed counselors, or trained peer facilitators do the work? What about traditional healers from indigenous lineages, many of whom have more hours in ceremony than any medical professional alive but no Western credential to show for it?

You can feel the field’s identity crisis in these submissions. Medicalizing psychedelics means playing by medicine’s rules, which were designed around pills and procedures, not around all-night ceremonies and master plants. Fit is awkward.

The Form Letter Campaigns and the Coordinated Opposition

Not everyone wrote in to help. A coordinated opposition — much of it recycling talking points about addiction risk, cult dynamics, and research methodology concerns — made up a meaningful slice of the comments. Some of these critiques are serious and worth engaging with (the quality of blinding in psychedelic trials really is a genuine scientific problem). Others are rehashes of drug-war rhetoric dressed up in clinical language.

The form-letter campaigns on the supportive side are also worth naming. Nearly a hundred submissions were template-driven, mostly from patient advocacy mobilizations. Regulators tend to discount these — a thousand identical letters count for less than ten thoughtful ones — but the sheer volume signals public interest, and that matters politically.

Oddly, at least one commenter forgot to delete the AI chatbot’s drafting notes from their submission. A sign of the times. For what it’s worth, serious submissions still read as the work of actual humans who’ve lived with these questions for years.

Where There’s Actually Common Ground

Underneath the disagreements, a surprising amount of consensus emerged. Almost everyone agrees that:

1. Current treatments for depression, PTSD, and substance use disorders are failing too many people, and the status quo is not acceptable.
2. Psychedelic-assisted therapy has shown enough signal in trials to warrant careful approval pathways, not blanket prohibition.
3. Safety screening matters — not every person is a candidate, and bad screening causes real harm.
4. Integration support after a session is not a luxury. It’s central to whether the experience translates into lasting change.
5. Access shouldn’t be gatekept purely by ability to pay $15,000 for a protocol.

That’s a lot of agreement for a field that loves to argue with itself.

What This Means If You’re Considering a Retreat

Here’s the honest read for someone weighing a booking right now. FDA approval of MDMA and psilocybin, whenever it lands, will not immediately change the landscape of international retreats offering ayahuasca, San Pedro, ibogaine, or psilocybin ceremonies. Those retreats operate under different legal frameworks — Peruvian, Costa Rican, Dutch, Jamaican, Mexican, Portuguese — and will continue to.

What approval will change is the broader conversation. More primary care doctors will understand what you mean when you say you did a plant medicine retreat. Insurance might eventually cover integration therapy. The stigma that still makes people hide their journeys from family will keep eroding. The underground will become less lonely.

If you’re thinking about addiction recovery specifically, pay close attention to the ibogaine conversation inside the docket. Ibogaine’s evidence base for interrupting opioid dependence is genuinely striking, and the regulatory path for it in the U.S. remains uphill. For most Americans, access still means traveling. That reality isn’t changing soon.

My advice, having sat with facilitators across several traditions: don’t wait for the FDA to tell you psychedelic healing is real. The research is useful and the regulation matters, but the decision in front of you is more personal than policy. Choose a reputable retreat, prepare honestly, and plan your integration before you book — not after. If any of this is pulling at you, a range of thoughtfully vetted psychedelic and plant-medicine retreats can be browsed on our marketplace here.

The docket will keep churning. Decisions will come. In the meantime, the ceremonies continue — in malocas and mountain cabins, in jungle lodges and quiet urban rooms — the way they have for a long time before any agency took interest.